XTX Topco Ltd Increases Stock Holdings in I-Mab (NASDAQ:IMAB)

XTX Topco Ltd grew its position in shares of I-Mab (NASDAQ:IMAB) by 140.8% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 43,039 shares of the company’s stock after buying an additional 25,163 shares during the quarter. XTX Topco Ltd owned 0.05% of I-Mab worth $53,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Garden State Investment Advisory Services LLC purchased a new position in I-Mab during the third quarter worth about $179,000. Bank of Montreal Can purchased a new position in shares of I-Mab during the 2nd quarter worth approximately $453,000. Finally, Caligan Partners LP lifted its holdings in shares of I-Mab by 3.7% in the 3rd quarter. Caligan Partners LP now owns 3,499,330 shares of the company’s stock valued at $4,339,000 after buying an additional 124,539 shares during the period. Institutional investors and hedge funds own 38.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of I-Mab in a research report on Friday, November 15th.

I-Mab Stock Performance

IMAB opened at $0.92 on Monday. The stock’s 50 day simple moving average is $1.09 and its 200 day simple moving average is $1.27. I-Mab has a 1-year low of $0.90 and a 1-year high of $2.54.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.